- Burtness B, Thomas L, Sipples R, McGurk M, Salikooti S, Christoforou M,?Mirto G, Salem R, Sosa J, Kloss R, Rahman Z, Chung G, Lacy J, Murren JR. Phase II Trial of Weekly Docetaxel/Irinotecan Combination in Advanced Pancreatic Cancer. Cancer J 13:257-62, 2
- Srimatkandada P, Loomis R, Carbone R, Srimatkandada S, Lacy J. Combined proteasome and Bcl-2 inhibition stimulates apoptosis and inhibits growth in EBV-transformed lymphocytes: a potential therapeutic approach to EBV-associated lymphoproliferative disease
- Mayer, T, Lacy, J, Baehring, J. A single institution’s experience with bevacizumab in combination with cytotoxic chemotherapy in progressive malignant glioma. Clinical Medicine: Oncology 2: 455-459, 2008
- Burtness, B, Gibson, MK, Lacy, J, Rowen, E, Thomas, L, Sipples, RE, McGurk, ML, Hahn, C, Murren, J, Forastiere, A. Phase II trial of docetaxel/irinotecan combination in advanced esophageal cancer. Annals Oncol 20:1242-48, 2009
- Canaan, A, Haviv, I, Urban, AE, Schulz, VP, Hartman, S, Zhang, A, Palejev, D, Deisseroth, AB, Lacy, J, Snyder, M, Gerstein, Weissman, SM. EBNA1 regulates cellular gene expression by binding cellular promoters. Proc Natl Acad Sci USA 106:22421-6, 2009.
- Seropian, S. and Lacy, J. Disorders of Lymphocytes. In Cecil Essentials of Medicine, Eighth Edition (Andreoli, TE, ed). Saunders Co. Philadelphia, PA. In Press.
- Podolstev, N, Lacy, J, Vose, J. Overview of the Lymphoid Neoplasms. In Lymphoma of the Nervous System 2nd edition (Batchelor, T, ed.). Butterworth-Heinemann, Philadelphia. In press.